Skip to main content

Table 2 Baseline characteristics and eGFR (Cr) at the time of renal biopsy, the time of treatment initiation, and each time point after treatment initiation

From: Long-term changes in renal function after treatment initiation and the importance of early diagnosis in maintaining renal function among IgG4-related tubulointerstitial nephritis patients in Japan

 

eGFR, mL/min/1.73m2 (Cr, mg/dL)

 

No.

Sex

Follow-up (yr)a

Primary diagnosis

Extrarenal lesions

PSL Tx (mg/day)

Duration of PSL treatment (yr)

At the time of renal biopsy

Baselineb

1 month from the baseline

2 months from the baseline

6 months from the baseline

12 months from the baseline

24 months from the baseline

36 months from the baseline

60 months from the baseline

The number of days between renal biopsy and the initiation of PSL treatment

Cases not diagnosed by renal biopsy at the initial examinationd

 1

M

13.7

TIN associated with immune disorder

Thr, Ca,

25

13.8

15.4 (3.32)

12.8 (3.95)

19.8 (2.64)

21.6 (2.44)

23.6 (2.25)

26.9 (1.99)

28.0 (1.91)

26.7 (1.99)

27.8 (1.9)

32

 2

M

7.8

TIN of Sjogren’s syndrome

Thr

30

2.5c

11.6 (3.24)

15.8 (3.22)

25.4 (2.08)

30.5 (1.76)

37.4 (1.46)

28.6 (1.86)

11.7 (4.19)

38.1 (1.42)

NA

− 17

 3

F

12.2

TIN of Sjogren’s syndrome

Ly, sinusitis, extrathoracic lesion

30

7.5

37.4 (1.2)

46.3 (1.3)

55.6 (1.1)

55.6 (1.1)

55.6 (1.1)

63.5 (0.97)

78.0 (0.8)

68.2 (0.9)

64.4 (0.94)

− 96

 4

M

9.3

TIN associated with immune disorder

Sa, Ly, Lu, Pa,

40

9.3

15.7 (3.5)

16.8 (3.29)

16.8 (3.29)

38.0 (1.56)

42.1 (1.42)

45.3 (1.32)

44.7 (1.33)

46.4 (1.28)

34.3 (1.67)

− 7

 5

M

11.0

Low-grade lymphoma

Sa, Ly, Thr

60

0.5c

34.3 (1.6)

34.3 (1.6)

NA

NA

NA

51.4 (1.1)

51.2 (1.1)

51.0 (1.1)

46.0 (1.21)

− 90

 6

M

7.8

TIN with immune complexes

Ca

40

7.8

16.6 (3.1)

16.6 (3.1)

37.3 (1.48)

37.9 (1.46)

37.1 (1.49)

34.6 (1.58)

33.3 (1.63)

35.1 (1.55)

23.3 (2.24)

− 14

Cases diagnosed by renal biopsy at the initial examination

 7

M

4.7

IgG4-related TIN

Sa, Ly, Lu, Thy, Pa

50

4.6

45.9 (1.25)

45.9 (1.25)

56.1 (1.04)

49.8 (1.16)

53.8 (1.08)

57.7 (1.01)

52.8 (1.09)

48.7 (1.17)

NA

− 23

 8

M

7.7

IgG4-related TIN

NA

40

1.9c

5.4 (9.0)

5.4 (9.0)

9.2 (5.51)

12.9 (4.04)

19.1 (2.82)

19.0 (2.82)

21.7 (2.49)

21.5 (2.5)

20.5 (2.59)

− 1

 9

M

6.9

IgG4-related TIN

NA

40

6.9

18.3 (2.86)

19.5 (2.82)

24.6 (2.18)

27.1 (2.0)

24.9 (2.16)

39.5 (1.41)

36.3 (1.52)

38.9 (1.42)

36.9 (1.48)

2

 10

M

7.3

IgG4-related TIN

Sa, Ly, La

50

7.0

54.0 (1.11)

59.0 (1.05)

59.0 (1.05)

68.0 (0.92)

73.0 (0.86)

54.0 (1.13)

62.0 (0.99)

59.0 (1.03)

56.0 (1.07)

− 36

 11

M

6.6

IgG4-related TIN

Ly, RPF

40

6.6

11.4 (4.35)

9.3 (5.25)

19.6 (2.65)

21.7 (2.41)

24.5 (2.16)

23.7 (2.21)

22.4 (2.33)

21.5 (2.41)

24.8 (2.1)

0

 12

M

4.6

IgG4-related TIN

Ly

50

4.6

7.5 (6.2)

7.5 (6.2)

22.0 (2.28)

29.0 (1.79)

29.0 (1.82)

25.0 (2.04)

27.0 (1.89)

24.0 (2.08)

26.0 (1.97)

− 2

 13

M

5.4

IgG4-related TIN

Sa, La, RPF

40

4.4c

12.4 (3.96)

12.4 (3.96)

28.7 (1.84)

28.4 (1.86)

29.8 (1.89)

32.2 (1.65)

36.3 (1.48)

32.4 (1.63)

29.3 (1.78)

− 12

 14

M

4.6

IgG4-related TIN

Ly

30

4.6

26.1 (2.06)

26.1 (2.06)

35.9 (1.54)

35.9 (1.54)

34.5 (1.59)

37.6 (1.47)

39.8 (1.39)

42.7 (1.3)

NA

− 10

 15

M

3.8

IgG4-related TIN

RPF, Ao

30

3.2

25.2 (2.08)

34.1 (1.58)

28.0 (1.89)

24.7 (2.12)

25.3 (2.07)

33.2 (1.61)

38.0 (1.42)

32.8 (1.62)

NA

− 14

 16

F

2.8

IgG4-related TIN

Ly, Lu

25

2.8

22.7 (1.7)

22.5 (1.7)

27.5 (1.42)

33.3 (1.19)

33.0 (1.2)

34.3 (1.16)

33.5 (1.18)

33.7 (1.17)

NA

− 13

 17

M

2.7

IgG4-related TIN

NA

30

2.7

9.3 (5.18)

6.7 (6.94)

12.1 (4.06)

16.6 (3.03)

15.7 (3.19)

19.0 (2.68)

16.6 (3.02)

NA

NA

− 5

 18

F

2.2

IgG4-related TIN

NA

30

0.8

4.3 (7.81)

3.5 (9.44)

12.1 (2.85)

13.0 (2.83)

11.6 (3.13)

12.3 (2.98)

11.6 (3.13)

NA

NA

18

 19

M

3.8

IgG4-related TIN

RPF, Ao

30

3.8

21.8 (2.39)

20.7 (2.51)

32.5 (1.66)

39.5 (1.39)

34.3 (1.58)

34.9 (1.55)

36.1 (1.5)

38.4 (1.41)

NA

5

 20

F

8.1

IgG4-related TIN

Sa, La

30

8.0

27.4 (1.53)

30.4 (1.39)

41.0 (1.06)

43.2 (1.01)

49.4 (0.89)

43.5 (1.0)

66.0 (0.68)

55.0 (0.8)

51.0 (0.85)

− 19

 21

M

7.8

IgG4-related TIN

Sa, Lu, Pa

45

7.7

49.5 (1.3)

49.5 (1.3)

87.7 (0.77)

70.5 (0.94)

84.7 (0.79)

80.3 (0.83)

83.1 (0.8)

92.6 (0.72)

80.4 (0.81)

− 13

 22

M

7.4

IgG4-related TIN

Sa, Ly

30

7.4

44.7 (1.27)

44.7 (1.27)

51.1 (1.12)

61.1 (0.95)

62.6 (0.93)

58.4 (0.99)

63.0 (0.92)

61.8 (0.93)

55.6 (1.02)

− 4

 23

M

6.7

IgG4-related TIN

Sa, Ly, RPF, Ca

30

6.2

55.8 (1.01)

52.7 (1.06)

63.1 (0.9)

52.7 (1.06)

65.4 (0.87)

52.5 (1.06)

53.4 (1.04)

52.1 (1.06)

NA

− 181

 24

M

4.9

IgG4-related TIN

Sa, RPF

35

4.4

31.4 (1.69)

31.4 (1.69)

55.2 (1.01)

63.3 (0.89)

45.1 (1.21)

48.1 (1.14)

51.9 (1.06)

47 (1.15)

NA

− 13

  1. Abbreviations: M men, F female, Yr year, TIN tubulointerstitial nephritis, PSL Tx initial dose of prednisolone, eGFR estimated glomerular filtration rate, Cr creatinine, NA not available, Ao periaortitis, Ca pericarditis, La dacryoadenitis, Lu lung lesion, Ly lymphadenitis, Pa type 1 autoimmune pancreatitis, RPF retroperitoneal fibrosis, Sa sialadenitis, Thr thrombocytopenia, Thy thyroiditis
  2. aLength of time between the renal biopsy and the last date of observation
  3. bThe baseline was the time of treatment initiation. If eGFR at the time of treatment initiation was not available, eGFR at the renal biopsy was used
  4. cThese patients were re-treated because of relapse after discontinuation of glucocorticoid
  5. dThis was because there were patients who had renal biopsy before IgG4-related TIN became a recognized entity. Patients in this group was not diagnosed with IgG4-related TIN during the observation period of the present study
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us